
Hansa Biopharma update - The European launch regains momentum

With the increased number of active centers, the complete enrolment of the European PAES study, and the record level of IDEFIRIX product sales is a welcome positive surprise. We continue to expect quarterly variations, which are now at a higher level and along a more positive, robust trend. We strongly welcome Renee Aguiar-Lucander as the new CEO, and the main near-term challenge is to secure growth capital.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Hansa Biopharma update - The European launch regains momentum